201 related articles for article (PubMed ID: 19408250)
1. Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21.
Kagan KO; Wright D; Etchegaray A; Zhou Y; Nicolaides KH
Ultrasound Obstet Gynecol; 2009 Jun; 33(6):657-64. PubMed ID: 19408250
[TBL] [Abstract][Full Text] [Related]
2. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Hoopmann M; Abele H; Alkier R; Lüthgens K
Ultrasound Obstet Gynecol; 2012 Nov; 40(5):530-5. PubMed ID: 22611005
[TBL] [Abstract][Full Text] [Related]
3. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
[TBL] [Abstract][Full Text] [Related]
4. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N;
J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
[TBL] [Abstract][Full Text] [Related]
5. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
6. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
[TBL] [Abstract][Full Text] [Related]
7. Prospective validation of first-trimester combined screening for trisomy 21.
Kagan KO; Etchegaray A; Zhou Y; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2009 Jul; 34(1):14-8. PubMed ID: 19526452
[TBL] [Abstract][Full Text] [Related]
8. Impact of bias in serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A multiples of the median levels on first-trimester screening for trisomy 21.
Wright D; Abele H; Baker A; Kagan KO
Ultrasound Obstet Gynecol; 2011 Sep; 38(3):309-13. PubMed ID: 21400623
[TBL] [Abstract][Full Text] [Related]
9. First-trimester combined screening for trisomy 21 at 7-14 weeks' gestation.
Wright D; Spencer K; Kagan K K; Tørring N; Petersen OB; Christou A; Kallikas J; Nicolaides KH
Ultrasound Obstet Gynecol; 2010 Oct; 36(4):404-11. PubMed ID: 20658511
[TBL] [Abstract][Full Text] [Related]
10. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.
Soergel P; Pruggmayer M; Schwerdtfeger R; Muhlhaus K; Scharf A
Fetal Diagn Ther; 2006; 21(3):264-8. PubMed ID: 16601335
[TBL] [Abstract][Full Text] [Related]
11. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
[TBL] [Abstract][Full Text] [Related]
12. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
[TBL] [Abstract][Full Text] [Related]
13. Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
Borenstein M; Persico N; Kagan KO; Gazzoni A; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jul; 32(1):5-11. PubMed ID: 18512854
[TBL] [Abstract][Full Text] [Related]
14. [Cross-validation of the first trimester screening algorithm of the FMF London on 38,700 pregnancies in Germany].
Lüthgens K; Abele H; Alkier R; Hoopmann M; Kagan KO
Ultraschall Med; 2011 Aug; 32(4):367-72. PubMed ID: 21667432
[TBL] [Abstract][Full Text] [Related]
15. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
[TBL] [Abstract][Full Text] [Related]
16. Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Bardani E; Nicolaides KH
Ultrasound Obstet Gynecol; 2020 Sep; 56(3):408-415. PubMed ID: 32621353
[TBL] [Abstract][Full Text] [Related]
17. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
[TBL] [Abstract][Full Text] [Related]
18. Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
Kagan KO; Cicero S; Staboulidou I; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2009 Mar; 33(3):259-64. PubMed ID: 19248005
[TBL] [Abstract][Full Text] [Related]
19. Impact of the maternal age-related risk in first-trimester combined screening for trisomy 21.
Abele H; Lüthgens K; Hoopmann M; Kagan KO
Fetal Diagn Ther; 2011; 30(2):135-40. PubMed ID: 21701138
[TBL] [Abstract][Full Text] [Related]
20. First-trimester screening for trisomy 21 using alpha-fetoprotein.
Bredaki FE; Wright D; Matos P; Syngelaki A; Nicolaides KH
Fetal Diagn Ther; 2011; 30(3):215-8. PubMed ID: 21952001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
